EE9900452A - HIV pöördtranskriptaasi inhibiitoritena kasulikud 4,4-kaksisasendatud-3,4-dihüdro-2(1H)-kinasolinoonid - Google Patents

HIV pöördtranskriptaasi inhibiitoritena kasulikud 4,4-kaksisasendatud-3,4-dihüdro-2(1H)-kinasolinoonid

Info

Publication number
EE9900452A
EE9900452A EEP199900452A EEP9900452A EE9900452A EE 9900452 A EE9900452 A EE 9900452A EE P199900452 A EEP199900452 A EE P199900452A EE P9900452 A EEP9900452 A EE P9900452A EE 9900452 A EE9900452 A EE 9900452A
Authority
EE
Estonia
Prior art keywords
disubstituted
dihydro
reverse transcriptase
transcriptase inhibitors
hiv reverse
Prior art date
Application number
EEP199900452A
Other languages
English (en)
Inventor
W. Corbett Jeffrey
Sung Ko Soo
Original Assignee
Dupont Pharmaceuticals Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dupont Pharmaceuticals Company filed Critical Dupont Pharmaceuticals Company
Publication of EE9900452A publication Critical patent/EE9900452A/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EEP199900452A 1997-04-09 1998-04-07 HIV pöördtranskriptaasi inhibiitoritena kasulikud 4,4-kaksisasendatud-3,4-dihüdro-2(1H)-kinasolinoonid EE9900452A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83854097A 1997-04-09 1997-04-09
US7132298P 1998-01-14 1998-01-14
PCT/US1998/006733 WO1998045276A2 (en) 1997-04-09 1998-04-07 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinones useful as hiv reverse transcriptase inhibitors

Publications (1)

Publication Number Publication Date
EE9900452A true EE9900452A (et) 2000-04-17

Family

ID=26752095

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900452A EE9900452A (et) 1997-04-09 1998-04-07 HIV pöördtranskriptaasi inhibiitoritena kasulikud 4,4-kaksisasendatud-3,4-dihüdro-2(1H)-kinasolinoonid

Country Status (19)

Country Link
EP (1) EP0973753A2 (et)
JP (1) JP2002504095A (et)
KR (1) KR20010006146A (et)
CN (1) CN1252063A (et)
AR (1) AR012340A1 (et)
AU (1) AU734928B2 (et)
BR (1) BR9808513A (et)
CA (1) CA2284996A1 (et)
EA (1) EA001991B1 (et)
EE (1) EE9900452A (et)
HR (1) HRP980143A2 (et)
HU (1) HUP0001446A3 (et)
IL (1) IL132188A0 (et)
NO (1) NO314936B1 (et)
NZ (1) NZ500592A (et)
PL (1) PL336305A1 (et)
SK (1) SK137899A3 (et)
TW (1) TW587078B (et)
WO (1) WO1998045276A2 (et)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3199099A (en) * 1998-03-27 1999-10-18 Du Pont Pharmaceuticals Company 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinthione derivatives, their preparation and their use as hiv reverse transcriptase inhibitors
WO2000021565A1 (en) 1998-10-13 2000-04-20 Du Pont Pharmaceuticals Company Selective eradication of virally-infected cells by combined use of a cytotoxic agent and an antiviral agent
CA2345516A1 (en) * 1998-11-19 2000-05-25 Dupont Pharmaceuticals Company Crystalline (-)-6- chloro-4- cyclopropylethynyl- 4-trifluoromethyl- 3,4-dihydro- 2(1h)-quinazolinone
HRP990359A2 (en) * 1998-11-19 2000-08-31 Du Pont Pharm Co A process for the preparation of quinazolinones
US6175009B1 (en) 1999-11-18 2001-01-16 Dupont Pharmaceuticals Company Process for the preparation of quinazolinones
EP1233950B1 (en) * 1999-11-23 2005-10-05 Smithkline Beecham Corporation 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/P39 kINASE INHIBITORS
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
US6555686B2 (en) 2000-03-23 2003-04-29 Bristol-Myers Squibb Pharma Asymmetric synthesis of quinazolin-2-ones useful as HIV reverse transcriptase inhibitors
WO2001070707A2 (en) * 2000-03-23 2001-09-27 Bristol-Myers Squibb Pharma Company Asymmetric synthesis of quinazolin-2-ones useful as hiv reverse transcriptase inhibitors
ZA200300255B (en) 2000-07-20 2004-09-28 Bristol Myers Squibb Pharma Co Tricyclic 2-pyridone compounds useful as HIV reverse transcriptase inhibitors.
US6596729B2 (en) 2000-07-20 2003-07-22 Bristol-Myers Squibb Company Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors
US8641644B2 (en) 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US7041068B2 (en) 2001-06-12 2006-05-09 Pelikan Technologies, Inc. Sampling module device and method
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8579831B2 (en) 2002-04-19 2013-11-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9795334B2 (en) 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US8784335B2 (en) 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US7547287B2 (en) 2002-04-19 2009-06-16 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7226461B2 (en) 2002-04-19 2007-06-05 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with sterility barrier release
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
AU2003295940A1 (en) * 2002-12-16 2004-07-29 Boehringer Ingelheim Pharmaceuticals, Inc. Treatment of hiv infection through combined administration of tipranavir and capravirine
US8574895B2 (en) 2002-12-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
WO2006001797A1 (en) 2004-06-14 2006-01-05 Pelikan Technologies, Inc. Low pain penetrating
EP1671096A4 (en) 2003-09-29 2009-09-16 Pelikan Technologies Inc METHOD AND APPARATUS FOR PROVIDING IMPROVED SAMPLE CAPTURING DEVICE
US9351680B2 (en) 2003-10-14 2016-05-31 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a variable user interface
EP1706026B1 (en) 2003-12-31 2017-03-01 Sanofi-Aventis Deutschland GmbH Method and apparatus for improving fluidic flow and sample capture
WO2006011062A2 (en) 2004-05-20 2006-02-02 Albatros Technologies Gmbh & Co. Kg Printable hydrogel for biosensors
US9775553B2 (en) 2004-06-03 2017-10-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
WO2005120365A1 (en) 2004-06-03 2005-12-22 Pelikan Technologies, Inc. Method and apparatus for a fluid sampling device
WO2009126900A1 (en) 2008-04-11 2009-10-15 Pelikan Technologies, Inc. Method and apparatus for analyte detecting device
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
CN102060786A (zh) * 2011-01-20 2011-05-18 天津大学 4-(取代-1,3-二炔基)-4-(三氟甲基)-3,4-二氢取代喹唑啉-2-酮类化合物及其制备方法和应用
US9839684B2 (en) * 2011-04-06 2017-12-12 Biovaxim Limited Pharmaceutical compositions comprising inactivated HIV viral particles and non-pathogenic lactobacilli for the induction of antigen-specific immunotolerance
EP2855483B1 (en) 2012-05-24 2017-10-25 Novartis AG Pyrrolopyrrolidinone compounds
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
WO2014115077A1 (en) 2013-01-22 2014-07-31 Novartis Ag Substituted purinone compounds
EP3412675A1 (en) 2013-05-27 2018-12-12 Novartis AG Imidazopyrrolidinone derivatives and their use in the treatment of disease
MX2015016421A (es) 2013-05-28 2016-03-03 Novartis Ag Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
AU2014272700B2 (en) 2013-05-28 2016-12-01 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
EA029269B1 (ru) 2013-11-21 2018-02-28 Новартис Аг Производные пирролопирролона и их применение для лечения заболеваний
CN116745269A (zh) * 2020-08-27 2023-09-12 默沙东有限责任公司 用于治疗hiv的作为选择性细胞毒性剂的二氢喹唑啉-2-酮衍生物
TW202517633A (zh) * 2023-07-07 2025-05-01 美商默沙東有限責任公司 作為選擇性細胞毒性劑之四氫喹唑啉衍生物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2436792A (en) * 1991-08-16 1993-03-16 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
IL102764A0 (en) * 1991-08-16 1993-01-31 Merck & Co Inc Quinazoline derivatives,and pharmaceutical compositions containing them
WO1993022292A1 (en) * 1992-05-07 1993-11-11 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
US5665720A (en) * 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
DE4320347A1 (de) * 1993-06-19 1994-12-22 Boehringer Mannheim Gmbh Quinazolin-Derivate und diese enthaltende Arzneimittel
GB2281297A (en) * 1993-08-27 1995-03-01 Merck & Co Inc Quinazoline compounds
WO1995012583A1 (en) * 1993-11-05 1995-05-11 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
US5434152A (en) * 1993-11-08 1995-07-18 Merck & Co., Inc. Asymmetric synthesis of (S)-(-)-6-chloro-4- cyclopropyl-3,4-dihydro-4-[(2-pyridyl)ethynyl]-2(1H)-quinazolinone

Also Published As

Publication number Publication date
JP2002504095A (ja) 2002-02-05
PL336305A1 (en) 2000-06-19
AR012340A1 (es) 2000-10-18
CA2284996A1 (en) 1998-10-15
EA199900907A1 (ru) 2000-04-24
EA001991B1 (ru) 2001-10-22
WO1998045276A3 (en) 1999-01-14
SK137899A3 (en) 2000-05-16
IL132188A0 (en) 2001-03-19
EP0973753A2 (en) 2000-01-26
TW587078B (en) 2004-05-11
HRP980143A2 (en) 1999-02-28
HUP0001446A3 (en) 2001-11-28
BR9808513A (pt) 2000-05-23
CN1252063A (zh) 2000-05-03
HUP0001446A2 (hu) 2001-05-28
NO314936B1 (no) 2003-06-16
AU6796098A (en) 1998-10-30
NZ500592A (en) 2001-09-28
WO1998045276A2 (en) 1998-10-15
KR20010006146A (ko) 2001-01-26
NO994904L (no) 1999-12-01
AU734928B2 (en) 2001-06-28
NO994904D0 (no) 1999-10-08

Similar Documents

Publication Publication Date Title
EE9900452A (et) HIV pöördtranskriptaasi inhibiitoritena kasulikud 4,4-kaksisasendatud-3,4-dihüdro-2(1H)-kinasolinoonid
DK0945443T3 (da) HIV-hæmmende pyrimidinderivater
DK1002795T3 (da) HIV-replikationsinhiberende pyrimidiner
FI20040309A7 (fi) Bentsoksatsinonit HIV-käänteistranskriptaasin estäjinä
DE122012000017I1 (de) Neuartige form von s-omeprazol.
DK0977737T3 (da) CRF-antagonistisk quino- og quinazoline
DE69840599D1 (de) Antimikrobielle chinolone, ihre zusammensetzungen und ihre verwendungen
SG80631A1 (en) Inhibitors of hiv reverse transcriptase
EE200200275A (et) Immunosupressantidena kasutatavad 2,4-diaminopürimidiiniühendid
FI953954L (fi) HIV:n käänteistranskriptaasin inhibiittoreita
ID24361A (id) Alat penyampur
ATE303388T1 (de) Substituierte 2-pyridinyl-6,7,8,9- tetrahydropyrimidoc1,2-aöpyrimidin-4-on- und 7- pyridinyl-2,3-dihydroimidazo-c1,2-aöpyrimidin- 5(1h)onderivate
DE60008353D1 (de) Hemihydrat von 16.alpha.-bromoepiandrosterone
AU4719699A (en) Substituted quinoxalin-2(1h)-ones useful as hiv reverse transcriptase inhibitors
ID21444A (id) Alat peredup
ATE277912T1 (de) Pyrimidine-2,4,6-trione als matrixmetalloproteinase-hemmer
AU3199099A (en) 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinthione derivatives, their preparation and their use as hiv reverse transcriptase inhibitors
DE59910200D1 (de) Kühlbares Bauteil
ZA982339B (en) 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors.
AU2003263838A1 (en) 4,4-disubstituted-3,4-dihydro-2(1h)-quinazoliniones useful as hiv reverse transcriptase inhibitors
AU4719799A (en) Substituted quinolin-2(1h)-ones useful as hiv reverse transcriptase inhibitors
DK0944603T3 (da) Fremgangsmåde til fremstilling af 2-amino-2-imidazolin-, guanidin- og 2-amino-3,4,5,6-tetrahydropyrimidin-derivater
AU5588400A (en) 1,4-benzodiazepin-2-ones useful as hiv reverse transcriptase inhibitors
DK0966464T3 (da) Substituerede 2,4-diaminopyrimidiner
ZA200004558B (en) Inhibitors of HIV reverse transcriptase.